1. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). (April 2022) Authors: Hernández-Bernal, Francisco; Ricardo-Cobas, Maria C.; Martín-Bauta, Yenima; Navarro-Rodríguez, Zadis; Piñera-Martínez, Marjoris; Quintana-Guerra, Joel; Urrutia-Pérez, Karen; Urrutia-Pérez, Klaudia; Chávez-Chong, Cristina O.; Azor-Hernández, Jorge L.; Rodríguez-Reinoso, José L.; Lobaina-Lambert, L... Journal: EClinicalMedicine Issue: Volume 46(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗